

Comprehensive Review on Sublingual Tablets of Tapentadol Hydrochloride.

¹Axit Patel, ²Darshan Patel, ³Mrs. Varsha Chaudhary, ⁴Mrs. Khushbu Patel, ⁵Dr. Pankaj Prajapati

¹Student (Department of Pharmaceutics) at Shri Sarvajanic Pharmacy College, Mehsana, Gujarat.

²Student (Department of Pharmaceutics) at Shri Sarvajanic Pharmacy College, Mehsana, Gujarat.

³Faculty (Department of Pharmaceutics) at Shri Sarvajanic Pharmacy College, Mehsana, Gujarat.

⁴Faculty (Department of Pharmaceutics) at Shri Sarvajanic Pharmacy College, Mehsana, Gujarat.

⁵Faculty (Department of Pharmaceutics) at Shri Sarvajanic Pharmacy College, Mehsana, Gujarat.

Corresponding Author: Axit Patel

Date of Submission: 01-04-2026

Date of Acceptance: 10-04-2026

Abstract

Sublingual drug delivery systems provide rapid systemic drug absorption through the oral mucosa, bypassing hepatic first-pass metabolism and improving bioavailability. Tapentadol hydrochloride, a centrally acting analgesic with dual mechanisms of μ -opioid receptor agonism and norepinephrine reuptake inhibition, is widely used for moderate to severe pain. However, its oral administration is associated with delayed onset and relatively low bioavailability (~32%), which can limit therapeutic efficiency. This review highlights the significance of sublingual tablets as an alternative delivery system for tapentadol hydrochloride. It discusses the physiology of sublingual absorption, formulation approaches, excipients, manufacturing techniques, and evaluation parameters. Sublingual delivery offers rapid onset, improved patient compliance, and enhanced therapeutic outcomes, making it a promising approach for pain management.

Keywords

Tapentadol hydrochloride, Sublingual tablets, Drug delivery system, Fast disintegration, Analgesic, Bioavailability

I. Introduction

Drug delivery systems are designed to optimize therapeutic efficacy by delivering drugs to the desired site of action with minimal side effects. Conventional oral dosage forms are widely used due to their convenience but often suffer from limitations such as delayed onset and first-pass metabolism.^[1]

Sublingual drug delivery is an advanced approach in which the drug is placed under the tongue and absorbed directly into systemic circulation through the highly vascularized mucosa. This route provides faster drug absorption (3–10 times higher than oral route) and avoids hepatic metabolism.^[2-3]

Tapentadol hydrochloride is a centrally acting analgesic with a dual mechanism of action, combining μ -opioid receptor agonism with norepinephrine reuptake inhibition. It is effective in treating both nociceptive and neuropathic pain. However, oral bioavailability is limited due to extensive metabolism, making it a suitable candidate for sublingual delivery.^[4]

II. Physiology of Sublingual Drug Delivery

The sublingual region is located beneath the tongue and contains a rich network of blood vessels, facilitating rapid drug absorption. The mucosal membrane is thin and permeable, allowing drugs to diffuse easily into systemic circulation.

After absorption, drugs directly enter venous circulation and bypass the gastrointestinal tract and liver metabolism. This results in faster onset of action and improved bioavailability compared to conventional oral administration.

Drug absorption through this route mainly occurs via passive diffusion and is influenced by factors such as lipophilicity, molecular weight, and drug concentration.^[5-6]

III. Advantages and Limitations of Sublingual Tablets

➤ Advantages^[7]

- Rapid onset of action
- Bypasses first-pass metabolism
- Improved bioavailability
- Suitable for pediatric and geriatric patients
- No need for water during administration
- Reduced dose and side effects
- Convenient self-administration

➤ Limitations^[8]

- Limited surface area for absorption
- Not suitable for high-dose drugs

- Taste masking is required
- Administration may be affected by saliva

IV. Tapentadol Hydrochloride: Drug Profile^[9-11]

Tapentadol hydrochloride is classified as a BCS Class I drug with high solubility and permeability. It exhibits a dual mechanism of action that enhances analgesic efficacy while reducing typical opioid-related adverse effects.

Molecular weight: 257.80 g/mol

Bioavailability: ~32% (oral)

Half-life: 4–5 hours

Mechanism: μ -opioid receptor agonist + norepinephrine reuptake inhibitor

Indication: Moderate to severe acute and chronic pain
Due to its pharmacokinetic limitations, sublingual delivery can significantly improve its onset and therapeutic performance.

V. Formulation of Sublingual Tablets

5.1 Components^[12-13]

Sublingual tablets require carefully selected excipients to ensure rapid disintegration and drug release:

API: Tapentadol hydrochloride

Diluents: Mannitol, lactose

Superdisintegrants: Croscopovidone, croscarmellose sodium

Binders: PVP

Lubricants: Magnesium stearate

Sweeteners and flavors: Improve palatability

5.2 Manufacturing Techniques^[14-15]

Various techniques are used for preparing sublingual tablets:

Direct Compression – Simple, cost-effective, widely used

Freeze Drying (Lyophilization) – Produces porous, fast-dissolving tablets

Molding – Provides rapid dissolution but low mechanical strength

Sublimation – Creates porous structure for fast disintegration

Spray Drying – Improves solubility and uniformity

Melt Granulation – Suitable for heat-stable drugs

VI. Evaluation Parameters of Sublingual Tablets^[16-17]

To ensure quality and performance, sublingual tablets are evaluated using:

1. General appearance:

- Tablet size and shape

- Colour and surface smoothness
- Odour and taste
- Presence of visible defects such as cracks or chips
- Clarity and legibility of any imprinted markings

2. Uniformity of weight: Weight uniformity will be assessed to verify that each tablet contains the correct quantity of active pharmaceutical ingredient (API). A total of twenty tablets will be weighed individually using a digital balance. The mean weight will be calculated, and deviations from the mean will be compared with pharmacopeial standards.

3. Hardness and thickness: The hardness of the tablets will be measured using a tablet hardness tester. Thickness will be determined using a vernier calliper.

4. Friability: Friability testing will determine the ability of tablets to resist abrasion and mechanical stress during handling. It will be performed using a Roche friabilator operating at 25 rpm for four minutes. After rotation, the percentage weight loss will be calculated using the formula:

$$\% \text{Friability} = \frac{(\text{Initial weight} - \text{Final weight})}{(\text{Initial weight})} \times 100$$

A friability of <1% is considered acceptable.

5. Wetting time: Wetting time will be measured to determine how quickly the tablet absorbs saliva or water, which indicates its potential disintegration behaviour. Each tablet will be placed on absorbent paper in a Petri dish containing a small amount of water, and the time taken for complete wetting will be recorded. The result will reflect the expected release rate of the drug in the oral cavity.

6. Disintegration time: The disintegration test will be performed either in 2 ml of distilled water in a test tube or using a USP disintegration apparatus without plastic disks. Tablets will be observed visually, typically at a 45° inclination, to ensure uniform wetting. Complete disintegration will be expected within two minutes to achieve a rapid onset of action.

7. In vitro dissolution study: The in vitro dissolution study will be carried out to determine the rate and extent of drug release from the tablet. The experiment will be conducted using a USP paddle-type dissolution apparatus. Samples will be collected at specific time intervals, filtered, and analysed spectrophotometrically. The percentage of drug release will be calculated based on a pre-established calibration curve to confirm consistent dissolution behaviour.

These parameters confirm rapid disintegration and effective drug release.

VII. Applications in Pain Management^[18-20]

Sublingual tablets are highly effective in conditions requiring rapid pain relief, including:

- Acute pain
- Cancer pain
- Neuropathic pain
- Migraine

Tapentadol's dual mechanism makes it particularly suitable for sublingual delivery, offering faster analgesic action and improved patient compliance.

VIII. Future Perspectives

Advancements in excipient technology and formulation strategies are expected to further enhance the performance of sublingual tablets. Novel approaches such as nanotechnology and bioadhesive systems may improve drug retention and absorption. Sublingual delivery of tapentadol hydrochloride holds significant potential in emergency and outpatient settings due to its rapid onset and ease of administration.

IX. Conclusion

Sublingual tablets represent an efficient and patient-friendly drug delivery system for rapid therapeutic action. Tapentadol hydrochloride, with its dual analgesic mechanism and favorable physicochemical properties, is an ideal candidate for sublingual formulation. This approach overcomes limitations of oral delivery by enhancing bioavailability, reducing onset time, and improving patient compliance. Therefore, sublingual tablets of tapentadol hydrochloride offer a promising strategy for effective pain management.

Reference:

- [1]. Tobechukwu CE, Ugochukwu SO, Ufedo L O, Chinenye PN. "Advances in drug delivery systems, challenges and future directions." *Heliyon*. **2023**, 9(6), e17488.
- [2]. Bahraminejad S, Almoazen H. "Sublingual and buccal delivery: a historical and scientific prescriptive." *Pharmaceutics*. **2025**, 17, 1073.
- [3]. Nayak BS, Subham S, Manaswini P, Subhasmita B. "Sublingual drug delivery system: a novel approach." *Int. J. Pharm. Anal.* **2017**, 10, 399- 405.
- [4]. Rama BR, Sukanya P, Abdul M, Khasim S, Shareef Sk, Janardhan T, Satish T. "Sublingual drug delivery system." *Int. J. Pharm. Res. & App.* **2024**, 9(1), 1194-1199.
- [5]. Mukul M, Aniket G, Rini P, Sanket D. "A review on sublingual tablets: an efficient alternative for drug administration." *Int. J. Pharm. Sci.* **2025**, 3(2), 1408-1418.
- [6]. Poonam P, Hemant G, Bhavana A. "Sublingual route for systemic drug delivery." *J. Drug Delivery & Therapeutics*. **2018**, 8(6s), 340-343.
- [7]. Dhanshree C, Vaishnavi C, Vaibhavi S, Vasudha S. "Sublingual drug delivery system: a detailed review." *Int. J. Res. Anal. Rew.* **2024**, 284-293.
- [8]. Sanjana L, Chaitali M, Vaishali R, Smita R. "Review on sublingual drug delivery system." *Journal of Drug Delivery and Therapeutics*. **2019**, 9(3), 684-688.
- [9]. Drug Bank . "Tapentadol (DB06204)." September 2025, <https://go.drugbank.com/drugs/DB06204>.
- [10]. Wikipedia, Tapentadol, September 2025, <https://en.wikipedia.org/wiki/Tapentadol>.
- [11]. Pubchem. "Tapentadol Hydrochloride (9838021)." September 2025, <https://pubchem.ncbi.nlm.nih.gov/#query=%22Tapentadol%20hydrochloride%22>.
- [12]. Priti D, Ritul G. "Formulation and evaluation of sublingual tablet of metoprolol succinate to improve patient compliance and bioavailability." *Int. J. Pharm. Sci. Res.* **2024**, 15(1), 257-264.
- [13]. Ruchita J, Ashutosh P, Dinesh K M, Jain D.K. "Sublingual tablets: an overview." *Journal of Drug Delivery Research*. **2014**, 3(4), 10-21.
- [14]. Kanade TS, Gupta A, Mahajan S, Darwhekar GN. "Review on sublingual tablets – a promising formulation for instant action." *Int. J. Pharm. Sci.* **2023**, 3(1),1-6.
- [15]. Rode PA, Malode AJ. "A review: on sublingual tablets." *Ind. J. Res. Methods Pharm. Sci.* **2022**, 1(6), 01-11.
- [16]. Malaykumar BC. "Overview of sublingual tablets." *Int. J. Pharm. Sci.* **2013**, 4(3), 151–170.
- [17]. Dimpal P, Sanjesh R. "Sublingual tablets: a review on state of art." *Int. J. Pharm. Sci.* **2018**, 9(1), 290-297.
- [18]. Jing W, Lisa V.D. "Clinical pain management: current practice and recent innovations in research." *Cell Reports Medicine*. **2024**, 5, 101786.
- [19]. Shuang L, Leigh K. "Physiology of pain – a narrative review on the pain pathway and its application in the pain management." *Dig Med Res.* **2022**, 5, 56.
- [20]. Mack A. Thomas, MD, FACS. "Pain management – the challenge." *The Ochsner Journal*. **2003**, 5(2), 15-21.